This post was originally published on this site A single infusion of KTE-X19, Kite Pharma‘s investigational CD19 CAR-T cell therapy, leads to high response rates in patients with relapsed or refractory acute lymphoblastic leukemia (ALL), Phase 1/2 trial data show. The findings were presented during an oral session titled, “End of phase I results of…
About Cancer
Cancer, also called malignancy, is an abnormal growth of cells with the potential to invade or spread to surrounding tissues and structures found within the body. There are more than 100 types of cancer. A few examples include breast cancer, skin cancer, lung cancer, colon cancer, prostate cancer, and lymphoma. According to the American Cancer Society, 4 out of 10 people will be diagnosed with some form of cancer in their lifetime. Cancer prevalence has given rise to multiple medical specialties focused on symptom management and disease management. Current treatment options depending on the form of cancer include chemotherapy, radiation, blood or bone marrow transfusions, and/or surgery. Lifetime prognosis of cancer mortality is dependent on the type of cancer and is heavily conditional to early detection.
Conditions
Cancer News
New AI-based Model Outperforms Current Methods of Predicting Breast Cancer Risk
This post was originally published on this site Scientists have created a new artificial intelligence (AI)-based model that outperforms current models at predicting the risks a woman has of developing breast cancer, and works equally well in white and African American women. The findings of the study, “A Deep Learning Mammography-based Model for Improved Breast…
Trial Shows Erleada Can Prolong Metastatic Castration-sensitive PC Patients’ Lives
This post was originally published on this site Adding Erleada (apalutamide), Janssen‘s next-generation androgen receptor inhibitor, to androgen deprivation therapy (ADT) can prolong life and extend the time without disease worsening in men with metastatic castration-sensitive prostate cancer, a Phase 3 trial shows. The findings — which supported Janssen’s application to the U.S. Food and…
Lynparza Better Than Chemo for BRCA-mutated Advanced Ovarian Cancer, Phase 3 Trial Shows
This post was originally published on this site Lynparza (olaparib), given to advanced ovarian cancer patients with BRCA mutations who were previously treated with at least two lines of platinum chemotherapy, had significantly better response rates and progression-free survival times than those given chemotherapy, full results from the SOLO-3 Phase 3 trial show. These findings make…
FDA Grants Priority Review to Darzalex Combo for Transplant-eligible Patients
This post was originally published on this site The U.S. Food and Drug Administration (FDA) has granted Priority Review to the supplemental Biologics License Application (sBLA) of Darzalex (daratumumab) in combination with standard pre-transplant therapy for the treatment of patients newly diagnosed with multiple myeloma who are eligible for autologous stem cell transplant (ASCT). The sBLA…
Cancer Vaccine Shows Potential against iNHL in Early Results
This post was originally published on this site A new cancer vaccine still in clinical testing showed potential for driving disease remission in patients with advanced indolent non-Hodgkin’s lymphoma (iNHL) and may help restore efficacy of immunotherapies, including checkpoint blockade therapies. The vaccine, administered directly to tumor lesions, was able to control or even shrink…
Phase 1/2 Trial of Immunotherapy AGI-134 to Open to US Patients with Solid Tumors
This post was originally published on this site BioLineRx is expanding the Phase 1/2 clinical trial of its investigational AGI-134 to include the U.S., now that regulatory officials there have approved the company’s request to test the treatment. The new sites are expected to open by mid-2020. The U.S. Food and Drug Administration’s favorable decision regarding its Investigational…
Pulmonary Hypertension Therapies May Help Heart Conditions in Certain Sarcoidosis Patients, Study Suggests
This post was originally published on this site While there no therapies approved for sarcoidosis-associated pulmonary hypertension (SAPH), pulmonary hypertension-specific therapies may help ease right heart dysfunction in a select group of patients, according to results of a large cohort study. The study, “Clinical Features and Outcomes of Patients with Sarcoidosis-associated Pulmonary Hypertension,” was published…
The Existential Clarity that Comes with Traveling with Cancer
This post was originally published on this site “Hi there … I’m loving your travel pics. I really wish I was able to travel while going through treatment! How do you do it?” The little red notification glared back at me from my Instagram inbox, demanding my attention. It was a message from one of…
Chemo Resistance in TNBC Due to Molecular Changes That May Be Treatable, Study Suggests
This post was originally published on this site Triple-negative breast cancer (TNBC) cells can become resistant to chemotherapy by temporarily turning on molecular pathways that protect the tumor, new research using mouse models and patient tumor samples uncovered. Since one of these pathways is a metabolic process possible to target, the study may offer new…
American and Russian Scientists Team Up in Search for Potential Biomarker for Metastatic Prostate Cancer
This post was originally published on this site Funded by a $380,000 grant from the National Cancer Institute, researchers at the University at Buffalo (UB) in New York and Moscow State University in Russia are collaborating to study a potential biomarker for metastatic prostate cancer, and determine how to best detect it. While some prostate…
OncBioMune’s Experimental Chemo Shows Potential to Inhibit Growth of Drug-resistant OC Cells
This post was originally published on this site PGT, an experimental chemotherapy developed by OncBioMune, inhibited the growth of ovarian cancer cells resistant to multiple chemotherapeutic agents. These preliminary results suggest that the therapy could potentially be used to treat tumors that do not respond to standard chemotherapy. PGT is a combination of paclitaxel, gallium,…